BERNARD ENNO ILSON
Medical Practice in Philadelphia, PA
License number
Pennsylvania MD031170E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Philadelphia, PA 19147
Personal information
See more information about BERNARD ENNO ILSON at radaris.comName
Address
Phone
613 Catharine St #A8, Philadelphia, PA 19147
711 Broadmoor Dr, Blue Bell, PA 19422
613 Union St, Philadelphia, PA 19147
613 Union Ct, Philadelphia, PA 19147
4040 Presidential Blvd, Philadelphia, PA 19131
Professional information
See more information about BERNARD ENNO ILSON at trustoria.com
At Medpace
At Medpace
Position:
Vice-President, Mediacl Affairs and Head, Nephrology Therapy Area at Medpace
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
Medpace
since Nov 2008
-
Vice-President, Mediacl Affairs and Head, Nephrology Therapy Area
Cardiokine, Inc
Apr 2005 - Feb 2008
-
Chief Medical Officer
University of Pennsylvania School of Medicine
Sep 1989 - Apr 2005
-
Clinical Assistant Professor of Medicine
GlaxoSmithKline
Mar 1987 - Apr 2005
-
Assoc Director, Director, Group Director
Education:
Temple University School of Medicine 1984 - 1986
Virginia Commonwealth University School of Medicine 1981 - 1984
New York University School of Medicine 1977 - 1981
MD, Medicine The University of Connecticut 1972 - 1977
BS, MS, Biology, Biochemistry
Virginia Commonwealth University School of Medicine 1981 - 1984
New York University School of Medicine 1977 - 1981
MD, Medicine The University of Connecticut 1972 - 1977
BS, MS, Biology, Biochemistry
Skills:
Clinical Development, Clinical Trials, Drug Development, Oncology, CRO, Diabetes, Clinical Research, Medical Affairs, Pharmaceutical Industry, Clinical Pharmacology, Endocrinology, FDA, Internal Medicine, Nephrology, Medicine
Dr. Bernard E Ilson - MD (Doctor of Medicine)
Dr. Bernard E Ilson - MD (Doctor of Medicine)
Hospitals:
613 Catharine St SUITE A-8, Philadelphia 19147
613 Catharine St SUITE A-8, Philadelphia 19147
613 Catharine St SUITE A-8, Philadelphia 19147
Education:
Medical Schools
New York University
Graduated: 1981
New York University
Graduated: 1981
Bernard Ilson, Philadelphia PA
Bernard Ilson, Philadelphia PA
Work:
Cardiokine, Inc.
30 S 15Th St, Philadelphia, PA 19102
30 S 15Th St, Philadelphia, PA 19102
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
US Patent:
2007001, Jan 18, 2007
Filed:
Sep 20, 2006
Appl. No.:
11/533542
Inventors:
Mireille Bonhomme - Les Ulis, FR
Antoine Bril - Les Ulis, FR
Bernard Gout - Les Ulis, FR
Bela Patel - King of Prussia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prussia PA, US
Bernard Ilson - Philadelphia PA, US
Antoine Bril - Les Ulis, FR
Bernard Gout - Les Ulis, FR
Bela Patel - King of Prussia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prussia PA, US
Bernard Ilson - Philadelphia PA, US
International Classification:
A61K 31/4965
US Classification:
514255030
Abstract:
The invention relates to the use of a 5-HTreceptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintainance dose, followed by administration of the SB 207266 or salt at the daily maintainance dose on subsequent days.
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
US Patent:
2008012, May 29, 2008
Filed:
Oct 31, 2007
Appl. No.:
11/930277
Inventors:
Mireille Marguerite Jeanne Bonhomme - Les Ulis, FR
Antoine Michel Alain Bril - Suresnes, FR
Bernard Emile Joseph Gout - Rennes, FR
Bela Rajiv Patel - King of Prussia PA, US
Gillian Louise Shepherd - Twickenham, GB
Neeta Balkrishan Amin - King of Prussia PA, US
Bernard Enno Ilson - Philadelphia PA, US
Antoine Michel Alain Bril - Suresnes, FR
Bernard Emile Joseph Gout - Rennes, FR
Bela Rajiv Patel - King of Prussia PA, US
Gillian Louise Shepherd - Twickenham, GB
Neeta Balkrishan Amin - King of Prussia PA, US
Bernard Enno Ilson - Philadelphia PA, US
International Classification:
A61K 31/5365, A61P 9/00
US Classification:
5142302
Abstract:
The invention relates to the use of a 5-HTreceptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof.The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base).The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintenance dose, followed by administration of the SB 207266 or salt at the daily maintenance dose on subsequent days.
The Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
The Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
US Patent:
2005003, Feb 10, 2005
Filed:
Aug 7, 2001
Appl. No.:
10/344075
Inventors:
Mireille Bonhomme - Les Ulis, FR
Antoine Michel Bril - Suresnes, FR
Bernard Emile Gout - Rennes, FR
Bela Patel - King of Prusia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prusia PA, US
Bernard Ilson - Philadelphia PA, US
Antoine Michel Bril - Suresnes, FR
Bernard Emile Gout - Rennes, FR
Bela Patel - King of Prusia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prusia PA, US
Bernard Ilson - Philadelphia PA, US
International Classification:
A61K009/00, A61K045/00
US Classification:
514400000, 424400000
Abstract:
The invention relates to the use of a 5-HTreceptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintainance dose, followed by administration of the SB 207266 or salt at the daily maintainance dose on subsequent days.